Biotest Aktiengesellschaft (0N70.L)

26.80 +0.30 (+1.13%) At close: 11:02AM BST

Biotest Aktiengesellschaft

Landsteinerstrasse 5
Dreieich 63303
Germany
49 61 03 801 0
https://www.biotest.com

Sector(s): 
Industry: 
Full-time employees: 2,426

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Peter Janssen	CEO & Chairman of the Board of Management	764k	N/A	1968
Ms. Ainhoa Mendizabal Zubiaga	Member of Management Board & CFO	570k	N/A	1973
Dr. Jorg Schuttrumpf	Chief Scientific Officer & Member of the Management Board	523k	N/A	1974
Dirk Schuck	Member of Supervisory Board	N/A	N/A	1978
Dr. Monika Buttkereit	Head of Investor Relations	N/A	N/A	N/A
Dr. Christina Erb	Head of Corporate HR	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols, S.A.

Corporate governance

Biotest Aktiengesellschaft’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.